IL132217A - Substained-release compositions and method for preparing same - Google Patents

Substained-release compositions and method for preparing same

Info

Publication number
IL132217A
IL132217A IL13221798A IL13221798A IL132217A IL 132217 A IL132217 A IL 132217A IL 13221798 A IL13221798 A IL 13221798A IL 13221798 A IL13221798 A IL 13221798A IL 132217 A IL132217 A IL 132217A
Authority
IL
Israel
Prior art keywords
composition
excipient
peptide
active substance
hormone
Prior art date
Application number
IL13221798A
Other languages
English (en)
Other versions
IL132217A0 (en
Original Assignee
Ipsen Pharma Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26233477&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL132217(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR9704837A external-priority patent/FR2762318B1/fr
Priority claimed from FR9803666A external-priority patent/FR2776516B1/fr
Application filed by Ipsen Pharma Biotech filed Critical Ipsen Pharma Biotech
Publication of IL132217A0 publication Critical patent/IL132217A0/xx
Publication of IL132217A publication Critical patent/IL132217A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y10T428/2985—Solid-walled microcapsule from synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL13221798A 1997-04-18 1998-04-17 Substained-release compositions and method for preparing same IL132217A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9704837A FR2762318B1 (fr) 1997-04-18 1997-04-18 Compositions presentant une liberation prolongee et leur procede de preparation
FR9803666A FR2776516B1 (fr) 1998-03-25 1998-03-25 Compositions presentant une liberation prolongee et leur procede de preparation
PCT/FR1998/000773 WO1998047489A1 (fr) 1997-04-18 1998-04-17 Compositions presentant une liberation prolongee et leur procede de preparation

Publications (2)

Publication Number Publication Date
IL132217A0 IL132217A0 (en) 2001-03-19
IL132217A true IL132217A (en) 2004-08-31

Family

ID=26233477

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13221798A IL132217A (en) 1997-04-18 1998-04-17 Substained-release compositions and method for preparing same

Country Status (23)

Country Link
US (2) US6217893B1 (hu)
EP (1) EP0980240B1 (hu)
JP (1) JP4557312B2 (hu)
CN (2) CN1144584C (hu)
AR (2) AR012448A1 (hu)
AT (1) ATE389388T1 (hu)
AU (1) AU741964B2 (hu)
BR (1) BR9808933A (hu)
CA (1) CA2286575C (hu)
CZ (1) CZ297078B6 (hu)
DE (1) DE69839264T2 (hu)
DK (1) DK0980240T3 (hu)
ES (1) ES2303353T3 (hu)
HK (1) HK1027983A1 (hu)
HU (1) HUP0004297A2 (hu)
IL (1) IL132217A (hu)
MY (1) MY118835A (hu)
NO (2) NO327999B1 (hu)
PL (1) PL196771B1 (hu)
PT (1) PT980240E (hu)
RU (1) RU2198678C2 (hu)
TW (1) TW577759B (hu)
WO (1) WO1998047489A1 (hu)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
TW577759B (en) * 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation
US6303138B1 (en) 1999-09-17 2001-10-16 Depuy Orthopaedics Endothelin-based compositions for enhancing connective tissue repair
CA2405709A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US20040161443A1 (en) * 2001-04-17 2004-08-19 Macneil Sheila Vehicle
US20030143191A1 (en) * 2001-05-25 2003-07-31 Adam Bell Chemokine beta-1 fusion proteins
CA2451187C (en) * 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
GB0122113D0 (en) * 2001-09-11 2001-10-31 Astrazeneca Ab Composition
EP1463752A4 (en) * 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
CA2471363C (en) * 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
CN1688696A (zh) * 2002-09-18 2005-10-26 蒙特利尔大学医疗中心 Ghrh类似物
AU2003303634B2 (en) * 2002-12-27 2009-10-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
CA2519779A1 (en) * 2003-03-26 2004-10-14 Teva Pharmaceutical Industries Ltd. A process for preparing a pharmaceutical active ingredient with high specific surface area
WO2004089279A2 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd. Long-acting derivatives of pyy agonists
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
CA2516107C (en) 2003-04-10 2013-12-24 Ehud Zeigerson A method for production of emulsion-based microparticles
WO2004096151A2 (en) * 2003-04-29 2004-11-11 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
JP5165239B2 (ja) * 2003-07-15 2013-03-21 ピーアール ファーマシューティカルズ， インコーポレイテッド 制御放出処方物の調製のための方法
WO2005009357A2 (en) * 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
ATE522548T1 (de) * 2003-11-13 2011-09-15 Hanmi Holdings Co Ltd Verfahren zur massenproduktion der konstanten region von immunglobulin
WO2005067889A1 (en) * 2003-12-30 2005-07-28 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
US20060110423A1 (en) * 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
MXPA06011924A (es) 2004-04-15 2007-06-11 Alkermes Inc Dispositivo de liberacion continua base polimeros.
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
EP2446894A3 (en) 2004-10-27 2013-02-20 University Of Denver Adrenocorticotropic hormone analogs and related methods
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ATE438385T1 (de) * 2005-03-02 2009-08-15 Secr Defence Pharmazeutische zusammensetzung
US8882747B2 (en) * 2005-11-09 2014-11-11 The Invention Science Fund I, Llc Substance delivery system
PL1968549T3 (pl) * 2005-12-22 2014-10-31 Novartis Ag Preparat o podtrzymywanym uwalnianiu zawierający okterotyd i dwa lub większą liczbę polimerów typu poli(mleczan-co-glikolan)
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
EP1837014A1 (en) * 2006-03-21 2007-09-26 Hexal Ag Subcutaneous implants containing a degradation-resistant polylactide polymer and a LH-RH analogue
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
JP2010522196A (ja) * 2007-03-22 2010-07-01 アルカームズ，インコーポレイテッド コアセルベーション工程
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EA019284B1 (ru) * 2007-06-06 2014-02-28 Дебиофарм Рисёрч Энд Мэньюфэкчуринг Са Фармацевтическая композиция с пролонгированным высвобождением, приготовленная из микрочастиц
US20080317865A1 (en) * 2007-06-20 2008-12-25 Alkermes, Inc. Quench liquids and washing systems for production of microparticles
KR101921800B1 (ko) * 2008-01-30 2018-11-23 노파르티스 아게 옥트레오티드 및 3종의 선형 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
PT2341905T (pt) * 2008-09-04 2020-07-27 Amylin Pharmaceuticals Inc Formulações de libertação sustentada utilizando transportadores não aquosos
KR101823699B1 (ko) 2009-09-28 2018-01-30 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
CN102686235A (zh) * 2010-01-04 2012-09-19 Mapi医药公司 包含格拉默或其药用盐的储药系统
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
IT1402654B1 (it) 2010-09-20 2013-09-13 Cid S R L Composizione per il rilascio di principi attivi da dispositivi di impianto
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103163258B (zh) * 2011-12-09 2015-09-23 山东绿叶制药有限公司 一种测定痕量曲普瑞林的方法
CN102552166A (zh) * 2012-01-09 2012-07-11 北京化工大学 一种溶菌酶/聚(α-氰基丙烯酸异丁酯)载药微球的制备方法
CN104394980B (zh) 2012-03-08 2018-10-09 康斯乔最高科学研究公司 具有光致变色性质的涂层、产生所述涂层的方法及其适用于光学制品和光滑表面的用途
EP2846767B1 (en) 2012-05-03 2022-01-26 Janssen Sciences Ireland Unlimited Company Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
RU2506269C1 (ru) * 2012-08-03 2014-02-10 Татьяна Георгиевна Емельянова Фармацевтическая композиция, содержащая физиологически активные гептапептиды, обладающие противосудорожным, анксиолитическим, центральным противовоспалительным и анальгетическим, а также антиалкогольным действием
WO2014169816A1 (zh) * 2013-04-18 2014-10-23 山东绿叶制药有限公司 戈舍瑞林缓释微球药物组合物
CN103230624A (zh) * 2013-05-02 2013-08-07 复旦大学附属上海市第五人民医院 一种用于微创埋线治疗的植入材料
CN103720663B (zh) * 2014-01-08 2016-04-06 昆药集团股份有限公司 一种促卵泡激素缓释微球及其制备方法
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
MX2017015504A (es) 2015-06-03 2018-05-15 Intarcia Therapeutics Inc Sistemas de colocacion y remoción de implante.
US10322169B2 (en) * 2015-06-10 2019-06-18 Evonik Roehm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
CN107224571A (zh) * 2016-03-23 2017-10-03 张巍 一种具有坐骨神经保护功能的plga复合微球
ITUA20162094A1 (it) 2016-03-29 2017-09-29 Cid S P A Perfezionamenti negli stent per il rilascio di principi attivi
CN105963258B (zh) 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
AU2017268161B2 (en) 2016-05-16 2020-03-12 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
EP3600553A4 (en) 2017-03-26 2020-09-02 Mapi Pharma Ltd. GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
CN107375910B (zh) * 2017-07-12 2020-03-24 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 PTHrP在制备治疗男性性腺功能低下综合征中的应用
CN110547969A (zh) * 2019-09-03 2019-12-10 杭州诺泰澳赛诺医药技术开发有限公司 一种高比表面积纳米级缓释微粉的生产工艺及设备
IT202000017191A1 (it) 2020-07-15 2022-01-15 Xbrane Biopharma Ab Procedimento senza acqua per preparare una composizione farmaceutica per un rilascio più prolungato e controllato di triptorelina o di un suo sale
CN112156170B (zh) * 2020-11-03 2022-10-21 北京康欣东弘医药科技有限公司 可供皮下注射的曲普瑞林缓释微球及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661206A5 (fr) 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
DE3734223A1 (de) * 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
US5021554A (en) * 1989-02-24 1991-06-04 Eli Lilly And Company Process for protein particle size reduction using a fluid-energy mill
GB2246514B (en) * 1990-08-01 1993-12-15 Scras Sustained release pharmaceutical compositions and the preparation of particles for use therein
GB9016885D0 (en) * 1990-08-01 1990-09-12 Scras Sustained release pharmaceutical compositions
DE4041563A1 (de) * 1990-12-22 1992-06-25 Sanol Arznei Schwarz Gmbh Verfahren zur herstellung wirkstoffhaltiger mikropartikel aus hydrolytisch abbaubaren polymeren
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
DE4223169C1 (de) * 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
EP0678018B1 (en) * 1993-01-06 2003-04-09 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5785976A (en) * 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
CA2218074C (en) * 1995-04-14 2002-10-08 Mohammed Eljamal Powdered pharmaceutical formulations having improved dispersibility
SK281571B6 (sk) * 1995-06-07 2001-05-10 Alkermes Controlled Therapeutics, Inc. Prostriedok na trvalé uvoľňovanie ľudského rastového hormónu
NZ325561A (en) * 1996-01-24 1999-06-29 Us Army Pharmaceutical composition containing an active ingredient and poly(lactide/glycolide) microcapsules which is a burst free controlled release formulation
TW577759B (en) * 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation

Also Published As

Publication number Publication date
WO1998047489A1 (fr) 1998-10-29
CN1144584C (zh) 2004-04-07
PL336296A1 (en) 2000-06-19
EP0980240B1 (fr) 2008-03-19
NO20080803L (no) 1999-11-15
ATE389388T1 (de) 2008-04-15
CN1256628A (zh) 2000-06-14
DK0980240T3 (da) 2008-07-28
TW577759B (en) 2004-03-01
CA2286575C (fr) 2012-06-05
CN1313082C (zh) 2007-05-02
EP0980240A1 (fr) 2000-02-23
JP2002500631A (ja) 2002-01-08
NO995063L (no) 1999-11-15
CZ362699A3 (cs) 2000-04-12
PL196771B1 (pl) 2008-01-31
PT980240E (pt) 2008-06-06
CN1494900A (zh) 2004-05-12
JP4557312B2 (ja) 2010-10-06
AR012448A1 (es) 2000-10-18
HK1027983A1 (en) 2001-02-02
AU741964B2 (en) 2001-12-13
ES2303353T3 (es) 2008-08-01
BR9808933A (pt) 2000-08-01
RU2198678C2 (ru) 2003-02-20
NO995063D0 (no) 1999-10-15
CA2286575A1 (fr) 1998-10-29
AR061828A2 (es) 2008-09-24
HUP0004297A2 (hu) 2001-08-28
AU7436398A (en) 1998-11-13
NO327999B1 (no) 2009-11-09
US6217893B1 (en) 2001-04-17
DE69839264D1 (de) 2008-04-30
US6475507B1 (en) 2002-11-05
CZ297078B6 (cs) 2006-09-13
DE69839264T2 (de) 2009-05-14
MY118835A (en) 2005-01-31
IL132217A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
AU741964B2 (en) Sustained-release compositions and method for preparing same
RU2103005C1 (ru) Фармацевтическая композиция продленного действия, используемая в ней полимерная композиция и способ ее получения
US6503534B1 (en) Pharmaceutical compositions for prolonged peptide release and preparation method
KR100293882B1 (ko) 카르복시말단폴리에스테르와펩티드와의염
EP0839525B1 (en) Sustained-release preparation
EP0904062B1 (en) Sustained release ionic conjugate
CA2110730C (en) Sustained-release preparation
US6630156B1 (en) Process for preparing biodegradable microspheres containing physiologically active agents
JPH07278277A (ja) 生体内分解性ポリマーの末端カルボキシル基におけるエステル
JP3524195B2 (ja) 徐放性製剤用基剤
MXPA99009496A (en) Sustained-release compositions and method for preparing same
FR2762319A1 (fr) Microcapsules presentant une liberation prolongee et leur procede de preparation
FR2776516A1 (fr) Compositions presentant une liberation prolongee et leur procede de preparation
FR2762318A1 (fr) Compositions presentant une liberation prolongee et leur procede de preparation

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired